북미 미만성 거대 B세포 림프종 치료제 시장 – 2024-2031년

Overview
The North America diffuse large B-cell lymphoma therapeutics market reached US$ 2017.11 million in 2023 and is expected to reach US$ 3577.3 million by 2031, growing at a CAGR of 7.6% during the forecast period 2024-2031.
Diffuse large B cell lymphoma (DLBCL) is a type of non-Hodgkin lymphoma (NHL). NHL is a type of blood cancer that affects white blood cells called lymphocytes. It is a cancer of the lymphatic system. Lymphoma develops when white blood cells called lymphocytes grow out of control. They move around the body in the blood and the lymphatic system. The lymphatic system is an important part of our immune system. It has tubes that branch through all parts of the body. 
These tubes are called lymph vessels or lymphatic vessels and they carry a straw-coloured liquid called lymph. This liquid circulates around the body tissues. It contains a high number of white blood cells (lymphocytes) which fight infection. DLBCL develops when the body makes abnormal B lymphocytes. So it is a type of B cell lymphoma. The abnormal lymphocytes build up in the lymph nodes or other body organs. They don't work properly. So they can't fight infection as normal white blood cells do.
Market Dynamics: Drivers
Increasing preference for targeted therapies
The increasing preference for targeted therapies propels the market growth. Targeted therapy is one of the most widely preferred methods for the treatment of diffuse large B-cell lymphoma, as targeted therapy is less toxic to healthy cells than chemotherapy. Targeted therapies act on specific molecular targets that are associated with cancer. Monoclonal antibodies, kinase inhibitors, immunomodulatory drugs, and nuclear export inhibitors are among the targeted therapies used for NHL. Rituximab is a targeted therapy that is used to treat a variety of B-cell NHL types. It works by focusing on a molecule known as CD20, which is found on the surface of both normal B cells and B-cell NHL cells. Ibrutinib is a targeted therapy that inhibits Bruton's tyrosine kinase pathway. 
Recent progress in molecular biology has led to a better understanding of the oncogenic drivers of DLBCL, resulting in the development of a large number of targeted therapies undergoing evaluation in phase I and II trials. Ibrutinib (Imbruvica), a targeted therapy approved by the FDA for use in multiple forms of lymphoma, has been tested in DLBCL to investigate if it affects the subtypes differently.
Restraints
Factors such as the high cost associated with the treatment are expected to hamper the market. The high cost associated with the treatment of diffuse large B-cell lymphoma is expected to restrain the market growth to a certain extent, as this limits the number of individuals undergoing the treatment. The cost to treat diffuse large B-cell lymphoma (RR DLBCL) can be high and that’s only taking into account first- and second-line treatments that can cost as much as $200,000.
Segment Analysis
The North America diffuse large B-cell lymphoma therapeutics market is segmented based on drug type and region.
The segment chemotherapy drugs accounted for approximately 48.3% of the North America diffuse large B-cell lymphoma therapeutics market share
The chemotherapy drugs segment is expected to hold the largest market share over the forecast period. In this segment, the increase in approvals, and rising funds for private manufacturers for clinical trials would drive this market. 
Diffuse large B-cell lymphoma (DLBCL) tends to grow quickly. Most often, the treatment is chemotherapy (chemo), usually with 4 drugs known as CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone), plus the monoclonal antibody rituximab (Rituxan). This regimen, known as R-CHOP, is most often given in cycles 3 weeks apart. Other chemo regimens may be used instead for people with heart problems or other serious health issues.
First-line treatment options for these lymphomas include R-CHOP and Pola-R-CHP, which is a combination of the monoclonal antibodies polatuzumab vedotin and rituximab and the chemo drugs cyclophosphamide, doxorubicin, and prednisone. Other regimens that include chemo and rituximab might be options as well.
Market Segmentation
By Drug Type
Chemotherapy Drugs
Targeted Drugs 
Rituximab
Polutuzumab vedotin-piiq
Pembrolizumab
Tisagenlecleucel
Ibrutinib
Others 
By End-User
Hospitals
Specialty Clinics
Others
Competitive Landscape
The major players in the North America diffuse large B-cell lymphoma therapeutics market include F. Hoffmann-La Roche Ltd, Novartis Pharmaceuticals Corporation, Celltrion Inc., Karyopharm, Gilead Sciences Inc., MorphoSys AG, AbbVie Inc., CTI BioPharma Corp, Seagen Inc., TG Therapeutics Inc. among others.
Key Developments
In 2023, the FDA approved the first bispecific T-cell engager agents, epcoritamab-bysp and glofitamab-gxbm. These two agents constitute new third-line options for patients with relapsed or refractory DLBCL.
In June 2024, Pfizer Inc. announced detailed overall survival (OS) results from the Phase 3 ECHELON-3 study of ADCETRIS® (brentuximab vedotin) in combination with lenalidomide and rituximab for the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). The study showed that the ADCETRIS combination reduced the patient’s risk of death by 37% compared to placebo in combination with lenalidomide and rituximab.
Why Purchase the Report?
To visualize the North America diffuse large B-cell lymphoma therapeutics market segmentation based on drug type and end-user as well as understand key commercial assets and players.
Identify commercial opportunities by analyzing trends and co-development.
Excel data sheet with numerous data points of North America diffuse large B-cell lymphoma therapeutics market level with all segments.
PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
Product mapping is available in Excel consisting of key products of all the major players.
The North America diffuse large B-cell lymphoma therapeutics market report would provide approximately 51 tables, 54 figures, and 181 Pages.
Target Audience 2024
Manufacturers/ Buyers
Industry Investors/Investment Bankers
Research Professionals
Emerging Companies